22 assets in Mucopolysaccharidosis Type 2

Therapeutic assets addressing Mucopolysaccharidosis Type 2, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Idursulfase Mucopolysaccharidosis Type 2	Takeda	P4	A (86)
Pabinafusp Alfa Mucopolysaccharidosis Type 2	JCR Pharmaceuticals Co., Ltd.	P3	BBB (78)
Rgx-121 Mucopolysaccharidosis Type 2	REGENXBIO Inc.	P3	BB (70)
Rituximab Mucopolysaccharidosis Type 2	Takeda	P4	BB (68)
Gnr-055 Mucopolysaccharidosis Type 2	AO GENERIUM	P2/3	BB (64)
Tividenofusp Alfa Mucopolysaccharidosis Type 2	Denali Therapeutics Inc.	P2/3	BB (64)
Human Immunoglobulins Mucopolysaccharidosis Type 2	Takeda	P4	B (62)
Methotrexate Mucopolysaccharidosis Type 2	Takeda	P4	B (60)
Busulfanum Mucopolysaccharidosis Type 2	Masonic Cancer Center, University of Minnesota	P2	B (57)
Cald Hr-D Mucopolysaccharidosis Type 2	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Adalimumab Mucopolysaccharidosis Type 2	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	P1/2	CCC (52)
Apoeii Mucopolysaccharidosis Type 2	University of Manchester	P1/2	CCC (48)
Autologous Cd34+ Cells Transduced With Tns9.3.55 Mucopolysaccharidosis Type 2	University of Manchester	P1/2	CCC (48)
Autologous Cd34+ Hscs Transduced Ex Vivo With Cd11B Lv Encoding Human Ids Tagged With Apoeii Mucopolysaccharidosis Type 2	University of Manchester	P1/2	CCC (48)
sb-913 Mucopolysaccharidosis Type 2	Sangamo Therapeutics	P1/2	CCC (48)
Verenafusp Alfa Mucopolysaccharidosis Type 2	AO GENERIUM	P1	CC (47)
Duoc-01 Mucopolysaccharidosis Type 2	Joanne Kurtzberg, MD	P1	CC (43)
gc1123 Mucopolysaccharidosis Type 2	GC Biopharma Corp	P1	CC (43)
Genetic Hmi-203 Mucopolysaccharidosis Type 2	Homology Medicines, Inc	P1	CC (43)
Iduronidase, .Alpha.-L-(8-Histidine) (Human) Mucopolysaccharidosis Type 2	University of California, San Francisco	P1	CC (43)